Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) Return on Sales (2021 - 2025)

Mirum Pharmaceuticals (MIRM) has 5 years of Return on Sales data on record, last reported at 0.04% in Q4 2025.

  • For Q4 2025, Return on Sales rose 20.0% year-over-year to 0.04%; the TTM value through Dec 2025 reached 0.04%, up 22.0%, while the annual FY2025 figure was 0.04%, 22.0% up from the prior year.
  • Return on Sales reached 0.04% in Q4 2025 per MIRM's latest filing, down from 0.02% in the prior quarter.
  • Across five years, Return on Sales topped out at 18.25% in Q4 2021 and bottomed at 9.42% in Q3 2021.
  • Average Return on Sales over 5 years is 0.42%, with a median of 0.49% recorded in 2023.
  • The widest YoY moves for Return on Sales: up 752bps in 2022, down -1956bps in 2022.
  • A 5-year view of Return on Sales shows it stood at 18.25% in 2021, then plummeted by -107bps to 1.31% in 2022, then surged by 61bps to 0.51% in 2023, then soared by 53bps to 0.24% in 2024, then skyrocketed by 84bps to 0.04% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 0.04% in Q4 2025, 0.02% in Q3 2025, and 0.05% in Q2 2025.